PD 158780

Drug Profile

PD 158780

Alternative Names: PD158780

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator New York University; Nonindustrial source; Pfizer
  • Developer New York University; Unknown
  • Class Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 4 receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Angelman syndrome
  • Discontinued Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Angelman-syndrome in USA (Infusion)
  • 01 Aug 2012 Preclinical trials in Angelman syndrome in USA (unspecified route) before August 2012
  • 01 Aug 2012 Pharmacodynamics data from a preclinical trial in in Angelman syndrome released by New York University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top